NacuGen Therapeutics

NacuGen Therapeutics is a preclinical-stage biotechnology company specializing in the development of advanced RNA-based medicines. The company utilizes its proprietary NacuGen platform, which focuses on the targeted delivery of nucleic acid conjugates to overcome the biological barriers that have historically limited the efficacy of oligonucleotide drugs. NacuGen's primary research focus is on small interfering RNA (siRNA) molecules designed to silence specific disease-causing genes, with a lead program targeting the STAT3 transcription factor. By precisely delivering these payloads to tumor cells and the immune microenvironment, the company aims to provide potent new treatment options for aggressive cancers such as glioblastoma and acute myeloid leukemia. NacuGen is built upon foundational research from world-renowned experts in RNA interference and nucleic acid chemistry.